Lantheus Business Model Canvas

Lantheus Holdings, Inc. Radiopharmaceuticals / Medical Imaging
Free preview

Key Partnerships

  • PET/CT scanner manufacturers (Siemens Healthineers, GE HealthCare, Philips)
  • Radiopharmacy networks (PETNet Solutions, UPPI)
  • Nuclear reactor operators (molybdenum-99 supply — NRU, OPAL)
  • Oncology diagnostics partners (prostate cancer staging)
  • Specialty pharmacy distributors
  • Clinical trial partners & research institutions
  • Reimbursement & payer relations consultants

Key Activities

  • Radiopharmaceutical manufacturing (PYLARIFY, DEFINITY, TechneLite)
  • Commercial sales & marketing (hospital, imaging center outreach)
  • Clinical pipeline development (therapeutic radiopharmaceuticals)
  • Regulatory management (FDA, EMA — nuclear medicine compliance)
  • Supply chain logistics (radioactive material handling & shipping)
  • Medical affairs & key opinion leader engagement
  • Reimbursement strategy & payer access programs

Key Resources

  • PYLARIFY brand franchise (PSMA PET — prostate cancer blockbuster)
  • DEFINITY brand franchise (#1 cardiac ultrasound contrast agent)
  • Radiopharmaceutical manufacturing facilities (cGMP compliant)
  • FDA-approved product portfolio & regulatory history
  • 1,000+ employees (manufacturing, sales, R&D)
  • Nuclear medicine expertise & radiochemistry capabilities
  • Distribution network reaching 3,000+ imaging centers
Free preview

Value Propositions

  • PYLARIFY — leading PSMA-targeted PET imaging for prostate cancer
  • DEFINITY — #1 ultrasound contrast agent for cardiac imaging
  • Growing pipeline of diagnostic & therapeutic radiopharmaceuticals
  • Decades of radiopharmacy manufacturing expertise
  • Reliable radioisotope supply chain (critical in healthcare)
  • Precision diagnostics enabling better treatment decisions
  • Reimbursement support making advanced imaging accessible

Customer Relationships

  • Dedicated account managers for hospitals & imaging centers
  • Medical education programs (nuclear medicine, PET imaging)
  • Reimbursement support services (insurance navigation for patients)
  • Clinical data sharing & evidence generation
  • Key opinion leader advisory boards
  • Customer service for ordering & logistics (time-sensitive products)
  • Professional society engagement (SNMMI, EANM)

Channels

  • Direct sales force (hospital & imaging center account managers)
  • Radiopharmacy distribution network (unit dose delivery)
  • Specialty distributors (regional coverage)
  • Medical conferences (SNMMI, ASCO GU, AUA)
  • lantheus.com product & clinical information
  • Medical affairs field teams
  • Digital marketing & physician education platforms
Free preview

Customer Segments

  • Nuclear medicine departments (hospitals & imaging centers)
  • Urologists & oncologists (prostate cancer staging with PYLARIFY)
  • Cardiologists (cardiac imaging with DEFINITY)
  • PET/CT imaging centers (standalone & hospital-based)
  • Hospital pharmacies (radiopharmaceutical procurement)
  • Radiopharmacies (unit dose preparation & delivery)
  • Academic medical centers (research & clinical use)

Cost Structure

  • Radiopharmaceutical manufacturing (specialized facilities, isotopes)
  • R&D expenses (pipeline development, clinical trials)
  • Sales force & commercial operations (direct hospital sales)
  • Isotope & raw material procurement (molybdenum-99, fluorine-18)
  • Regulatory compliance & quality assurance (nuclear medicine)
  • Distribution & logistics (radioactive material shipping — time-critical)
  • Employee compensation (1,000+ specialized workforce)

Revenue Streams

  • PYLARIFY sales (largest — PSMA PET for prostate cancer, $1B+ run rate)
  • DEFINITY sales (cardiac ultrasound contrast — steady growth)
  • TechneLite generator sales (technetium-99m — legacy product)
  • Other diagnostic imaging product sales
  • Strategic partnership milestones & royalties
  • Pipeline product future revenue (therapeutic radiopharmaceuticals)
  • Manufacturing services & contract production

Lantheus Business Model Canvas: Complete BMC Analysis

The Lantheus Business Model Canvas reveals how this North Billerica, Massachusetts-based company became the leader in radiopharmaceutical diagnostics with blockbuster products PYLARIFY (PSMA PET imaging for prostate cancer) and DEFINITY (microbubble contrast agent for cardiac ultrasound). This BMC framework analysis covers Lantheus's nine building blocks.

Value Propositions in Lantheus's BMC

Lantheus's Value Propositions include PYLARIFY — the leading PSMA-targeted PET imaging agent for prostate cancer detection, DEFINITY — the #1 ultrasound contrast agent for cardiac imaging, a growing pipeline of diagnostic and therapeutic radiopharmaceuticals, and decades of radiopharmacy manufacturing expertise. This diagnostic imaging leadership complements the Philips Business Model Canvas imaging equipment and the Siemens Business Model Canvas Healthineers division.

Customer Segments Analysis

Lantheus's Customer Segments include nuclear medicine departments, urologists and oncologists (prostate cancer staging), cardiologists (cardiac imaging), PET/CT imaging centers, hospital pharmacies, and radiopharmacies. The Microbot Medical Business Model Canvas targets similar hospital-based procedural departments.

Key Partners and Key Resources

The Key Partners include PET/CT scanner manufacturers (Siemens, GE, Philips), radiopharmacy networks (PETNet, UPPI), nuclear reactor operators (molybdenum-99 supply), oncology diagnostics partners, and specialty pharmacy distributors. Key Resources encompass PYLARIFY and DEFINITY brand franchises, radiopharmaceutical manufacturing facilities, FDA-approved product portfolio, 1,000+ employees, and nuclear medicine expertise.

Revenue Streams and Cost Structure

Lantheus's Revenue Streams come from PYLARIFY sales (largest — prostate cancer PET), DEFINITY sales (cardiac ultrasound), other diagnostic products (TechneLite), and pipeline milestones. The Cost Structure includes radiopharmaceutical manufacturing, R&D, sales force, regulatory compliance, and isotope procurement. Compare this to the J&J Business Model Canvas medical devices and the Bayer Business Model Canvas radiology products.

Channels and Customer Relationships

Lantheus's Channels include direct sales force (hospital and imaging center sales), radiopharmacy distribution network, specialty distributors, and medical conference marketing. Customer Relationships leverage dedicated account managers, medical education programs, reimbursement support services, and clinical data sharing.

Key Activities in the BMC Framework

Lantheus's Key Activities include radiopharmaceutical manufacturing, commercial sales and marketing, clinical pipeline development, regulatory management, and supply chain logistics (radioactive materials). These activities advance alongside the Philips Business Model Canvas and Siemens Business Model Canvas imaging technology ecosystems.

Comparing Medical Imaging & Diagnostics Business Model Canvases

Study related BMC analyses: the Philips BMC for imaging equipment, Siemens BMC for Healthineers, J&J BMC for medical devices, Bayer BMC for radiology, and Microbot Medical BMC for surgical robotics. Also explore: Allarity Therapeutics BMC for precision oncology and Intellia Therapeutics BMC for gene therapy.

Build your own canvas like Lantheus Holdings, Inc.'s

Use Lantheus Holdings, Inc.'s model as a blueprint. Create, customize and export your own Business Model Canvas in minutes.

Start building — free
Full access for 7 days · No charge · Cancel anytime 30-day money-back guarantee

Frequently asked questions about Lantheus Holdings, Inc.

How does Lantheus Holdings, Inc. make money?

Lantheus Holdings, Inc. makes money primarily through PYLARIFY sales (largest — PSMA PET for prostate cancer, $1B+ run rate), DEFINITY sales (cardiac ultrasound contrast — steady growth), TechneLite generator sales (technetium-99m — legacy product), Other diagnostic imaging product sales, Strategic partnership milestones & royalties and Pipeline product future revenue (therapeutic radiopharmaceuticals). These revenue streams are the foundation of Lantheus Holdings, Inc.'s business model and show how the company monetizes the value it creates for its customers.

What is Lantheus Holdings, Inc.'s business model?

Lantheus Holdings, Inc.'s business model is built on delivering PYLARIFY — leading PSMA-targeted PET imaging for prostate cancer, DEFINITY — #1 ultrasound contrast agent for cardiac imaging, Growing pipeline of diagnostic & therapeutic radiopharmaceuticals, Decades of radiopharmacy manufacturing expertise, Reliable radioisotope supply chain (critical in healthcare) and Precision diagnostics enabling better treatment decisions. It targets Nuclear medicine departments (hospitals & imaging centers), Urologists & oncologists (prostate cancer staging with PYLARIFY), Cardiologists (cardiac imaging with DEFINITY), PET/CT imaging centers (standalone & hospital-based), Hospital pharmacies (radiopharmaceutical procurement) and Radiopharmacies (unit dose preparation & delivery) and generates revenue from PYLARIFY sales (largest — PSMA PET for prostate cancer, $1B+ run rate), DEFINITY sales (cardiac ultrasound contrast — steady growth), TechneLite generator sales (technetium-99m — legacy product), Other diagnostic imaging product sales, Strategic partnership milestones & royalties and Pipeline product future revenue (therapeutic radiopharmaceuticals), mapped across the nine building blocks of the Business Model Canvas.

Who are Lantheus Holdings, Inc.'s target customers?

Lantheus Holdings, Inc. primarily serves Nuclear medicine departments (hospitals & imaging centers), Urologists & oncologists (prostate cancer staging with PYLARIFY), Cardiologists (cardiac imaging with DEFINITY), PET/CT imaging centers (standalone & hospital-based), Hospital pharmacies (radiopharmaceutical procurement) and Radiopharmacies (unit dose preparation & delivery). Understanding these customer segments is key to how Lantheus Holdings, Inc. designs its products, pricing and go-to-market strategy.

What is Lantheus Holdings, Inc.'s value proposition?

Lantheus Holdings, Inc.'s core value propositions are PYLARIFY — leading PSMA-targeted PET imaging for prostate cancer, DEFINITY — #1 ultrasound contrast agent for cardiac imaging, Growing pipeline of diagnostic & therapeutic radiopharmaceuticals, Decades of radiopharmacy manufacturing expertise, Reliable radioisotope supply chain (critical in healthcare) and Precision diagnostics enabling better treatment decisions. These are the main reasons customers choose Lantheus Holdings, Inc. over the alternatives.

Who are Lantheus Holdings, Inc.'s key partners?

Lantheus Holdings, Inc. works with key partners such as PET/CT scanner manufacturers (Siemens Healthineers, GE HealthCare, Philips), Radiopharmacy networks (PETNet Solutions, UPPI), Nuclear reactor operators (molybdenum-99 supply — NRU, OPAL), Oncology diagnostics partners (prostate cancer staging), Specialty pharmacy distributors and Clinical trial partners & research institutions. These partnerships help Lantheus Holdings, Inc. reduce risk, access resources and scale its business model.

What are Lantheus Holdings, Inc.'s main costs?

Lantheus Holdings, Inc.'s cost structure is driven mainly by Radiopharmaceutical manufacturing (specialized facilities, isotopes), R&D expenses (pipeline development, clinical trials), Sales force & commercial operations (direct hospital sales), Isotope & raw material procurement (molybdenum-99, fluorine-18), Regulatory compliance & quality assurance (nuclear medicine) and Distribution & logistics (radioactive material shipping — time-critical). Managing these costs efficiently is central to Lantheus Holdings, Inc.'s profitability and long-term sustainability.